세계의 통증 관리 기기 시장 예측(2024-2029년)

The global pain management devices market is projected to witness a compounded annual growth rate of 12.38% to reach US$13.217 billion by 2029, up from US$5.843 billion in 2022.

Rising chronic diseases and the geriatric population are the key factors influencing the global pain management devices market. To manage pain, a precise combination of medicines or equipment is used. Pain management devices include transcutaneous electrical nerve triggers, neuro-triggers, the absence of pain mixture siphons, and radiofrequency ablators. A large portion of these devices blocks the pain entryway component to impede the section of pain signs to the mind.

Radiofrequency ablators obliterate nerves by creating warmth to impede the pain signals. Similarly, neuro-trigger devices utilize gentle frequencies of current to obstruct the entry of pain signals. These devices offer assistance in treating distinctive painful conditions like the growth of malignant, musculoskeletal damage, and neuropathic torment. Pain management instruments offer assistance to diminish the threat of long-haul sedatives, non-steroidal calming drugs, and other pain-mitigating medicines.

The Centers for Disease Control and Prevention evaluated that 50 million people within the US endure persistent and chronic daily pain, with adults accounting for 19.6 million that have high-impact chronic and unremitting pain that meddling with their capacity to live their day-to-day lives or their occupations. This is adding to the health care burden of several countries.

The market for pain management devices is appealing as technology, wearables, and gadgets become more integrated into customers' daily lives, and consumer interest in these products shifts from novelty to more widely used pain management techniques.

Market Driver:

• The growing geriatric population is anticipated to surge the market growth.

People are living longer than ever before worldwide owing to better healthcare facilities and fewer wars. Longer lifespans correspond to a higher occurrence of pain; thus, there is an increasing need to prevent and reduce this discomfort.

The rising number of individuals that over 65 is anticipated to contribute to the pain management devices market expansion. According to the World Bank, in 2021, 9.54% of the population was above 65 years of age. Further, as per the United Nations (UN) statistics for World Population Prospects 2019, the world population is anticipated to rise in the next 30 years, from 7.7 billion in the year 2019 to 9.7 billion in 2050, and the global elderly population is also rising. Thus, with rising elderly population suffers from chronic back pain and arthritis which will lead to a rise in the market. For instance, in December 2023, SPR Therapeutics completed enrollment in the RESET Clinical Trial of the SPRINT(R) PNS System for chronic low back pain (LBP), the largest prospective, multicenter randomized controlled trial to date. The trial compares percutaneous peripheral nerve stimulation (PNS) with standard interventional treatments for chronic LBP.

Increasing the number of surgical procedures carried out will bolster the market growth.

The market for pain management devices is being driven altogether by the rise in surgical operations. The rising rate of long-term sicknesses such as cancer and neurological issues has raised the requirement for surgical methods, which has, in turn, raised the requirement for pain alleviation innovation. The requirement for pain management instruments has also been extended by progresses in innovation and the appearance of negligibly intrusive methods.

Also, it is expected that the market will rise due to the developing accentuation on early illness discovery and treatment, rising awareness of healthcare management among the public, growing healthcare services access, and an increase in government programs to bolster healthcare, will drive the market.

Market Restraints:

• Side effects associated with using painkillers as a first resort for pain management

Pain medications are frequently the primary line of treatment due to potential side effects such as sickness, drowsiness, constipation, and nausea. Addictive medications can further complicate the situation. Alternative pain management methods, such as pain management devices, can reduce pain without medication. These devices can be used alongside physical therapy or as standalone treatments, reducing side effects and improving pain management.

North America is expected to dominate the market share.

North America has a significant place in the pain management devices market due to its expansive healthcare sector, prominent investment in healthcare, innovative technology, rising chronic pain incidences, environment regulations, and accessibility to healthcare administrations for all regions. The US is also known for its progressed and advanced infrastructure of healthcare and accentuation on advancement in technology.

For instance, in September 2023, Boston Scientific, a US-based medical device manufacturer, announced an agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that developed and commercialized the Intracept(R) Intraosseous Nerve Ablation System for treating heterogenic pain, a form of chronic low back pain. The transaction includes an upfront cash payment of $850 million and additional contingent payments based on sales performance over the next three years. The Intercept system is the only U.S. Food and Drug Administration-cleared system for heterogenic pain, a minimally invasive, implant-free outpatient procedure that uses targeted radiofrequency energy to improve function and provide long-term relief.

The predominance of persistent pain due to an elderly populace and wrong lifestyle issues may drive the rising demand for pain administration devices in North America. The regulatory initiatives in North America, especially the US, assist the advancement, endorsement, and commercialization of medical devices that manage pain, cultivating innovation and expansion. This accessibility to healthcare services contributes to the higher adoption rate of pain management devices.

Key Developments:

• April 2024- Medtronic received FDA approval for its Inceptiv(TM) closed-loop spinal cord stimulator, which is designed to treat chronic pain. The device, the first Medtronic SCS to offer a closed-loop feature, automatically adjusts stimulation in real-time based on biological signals along the spinal cord, ensuring therapy is in harmony with daily life motions.
• December 2023- Nexstim received an order for two NBS 6 systems from a distributor company, which are now more user-friendly and approved for treating major depressive disorder (MDD) in the US and EU, as well as chronic neuropathic pain in the EU.
• August 2023- Zynex, Inc. introduced three new therapy products for pain management. The first is the Zynex Pro Thoracic Lumbar Sacral Orthosis, a dual-purpose back brace for the spine; the second is the Zynex Pro Wrist, a wrist brace for wrist-related pain management, including carpal tunnel syndrome; and the third is the Zynex Cryoheat, a localized fluid therapy system for home or hospital use.
• January 2023- CoachCare, a leading RPM and virtual health company acquired Winston-Salem-based NVOLVE for an undisclosed amount, adding NVOLVE's expertise in pain, spine, and orthopedic specialties to its services across South Carolina, North Carolina, Georgia, Texas, Tennessee, and Virginia. FCA Venture Partners is a venture capital firm that invests in early-stage healthcare technology and technology-enabled services companies, while CoachCare, a New York-based remote patient monitoring and virtual health company, offers complete RPM support services.
• August 2022- Abbott received FDA approval for its Proclaim(TM) Plus spinal cord stimulation system, which offers tailored relief to multiple painful areas and offers more treatment options for evoking pain conditions. The FlexBurst360 therapy, the next generation of Abbott's proprietary BurstDR(TM) stimulation, can be adjusted as a person's therapeutic needs evolve.

Market Segmentation:

Global Pain Management Devices Market is segmented and analyzed as below:

By Devices

• Electrical Stimulators
• Neurostimulation Devices
• Analgesic Infusion Pumps
• Ablation Devices

By Application

• Facial & Migraine Pain
• Neuropathic Pain
• Cancer Pain
• Musculoskeletal Pain
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• UK
• Germany
• Italy
• France
• Others
• Middle East and Africa
• Israel
• Saudi Arabia
• Others
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Taiwan
• Thailand
• Indonesia
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key Benefits to the Stakeholder

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Processes

3. EXECUTIVE SUMMARY

• 3.1. Key Findings

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis
• 4.5. Analyst View

5. GLOBAL PAIN MANAGEMENT DEVICES MARKET BY DEVICES

• 5.1. Introduction
• 5.2. Electrical Stimulators
  • 5.2.1. Market Opportunities and Trends
  • 5.2.2. Growth Prospects
  • 5.2.3. Geographic Lucrativeness
• 5.3. Neurostimulation Devices
  • 5.3.1. Market Opportunities and Trends
  • 5.3.2. Growth Prospects
  • 5.3.3. Geographic Lucrativeness
• 5.4. Analgesic Infusion Pumps
  • 5.4.1. Market Opportunities and Trends
  • 5.4.2. Growth Prospects
  • 5.4.3. Geographic Lucrativeness
• 5.5. Ablation Devices
  • 5.5.1. Market Opportunities and Trends
  • 5.5.2. Growth Prospects
  • 5.5.3. Geographic Lucrativeness

6. GLOBAL PAIN MANAGEMENT DEVICES MARKET BY APPLICATION

• 6.1. Introduction
• 6.2. Facial & Migraine Pain
  • 6.2.1. Market Opportunities and Trends
  • 6.2.2. Growth Prospects
  • 6.2.3. Geographic Lucrativeness
• 6.3. Neuropathic Pain
  • 6.3.1. Market Opportunities and Trends
  • 6.3.2. Growth Prospects
  • 6.3.3. Geographic Lucrativeness
• 6.4. Cancer Pain
  • 5.5.1. Market Opportunities and Trends
  • 5.5.2. Growth Prospects
  • 5.5.3. Geographic Lucrativeness
• 6.5. Musculoskeletal Pain
  • 6.5.1. Market Opportunities and Trends
  • 6.5.2. Growth Prospects
  • 6.5.3. Geographic Lucrativeness
• 6.6. Others
  • 6.6.1. Market Opportunities and Trends
  • 6.6.2. Growth Prospects
  • 6.6.3. Geographic Lucrativeness

7. GLOBAL PAIN MANAGEMENT DEVICES MARKET BY GEOGRAPHY

• 7.1. Introduction
• 7.2. North America
  • 7.2.1. By Devices
  • 7.2.2. By Application
  • 7.2.3. By Country
    • 7.2.3.1. USA
      • 7.2.3.1.1. Market Opportunities and Trends
      • 7.2.3.1.2. Growth Prospects
    • 7.2.3.2. Canada
      • 7.2.3.2.1. Market Opportunities and Trends
      • 7.2.3.2.2. Growth Prospects
    • 7.2.3.3. Mexico
      • 7.2.3.3.1. Market Opportunities and Trends
      • 7.2.3.3.2. Growth Prospects
• 7.3. South America
  • 7.3.1. By Devices
  • 7.3.2. By Application
  • 7.3.3. By Country
    • 7.3.3.1. Brazil
      • 7.3.3.1.1. Market Opportunities and Trends
      • 7.3.3.1.2. Growth Prospects
    • 7.3.3.2. Argentina
      • 7.3.3.2.1. Market Opportunities and Trends
      • 7.3.3.2.2. Growth Prospects
    • 7.3.3.3. Others
      • 7.3.3.3.1. Market Opportunities and Trends
      • 7.3.3.3.2. Growth Prospects
• 7.4. Europe
  • 7.4.1. By Devices
  • 7.4.2. By Application
  • 7.4.3. By Country
    • 7.4.3.1. UK
      • 7.4.3.1.1. Market Opportunities and Trends
      • 7.4.3.1.2. Growth Prospects
    • 7.4.3.2. Germany
      • 7.4.3.2.1. Market Opportunities and Trends
      • 7.4.3.2.2. Growth Prospects
    • 7.4.3.3. Italy
      • 7.4.3.3.1. Market Opportunities and Trends
      • 7.4.3.3.2. Growth Prospects
    • 7.4.3.4. France
      • 7.4.3.4.1. Market Opportunities and Trends
      • 7.4.3.4.2. Growth Prospects
    • 7.4.3.5. Others
      • 7.4.3.5.1. Market Opportunities and Trends
      • 7.4.3.5.2. Growth Prospects
• 7.5. Middle East and Africa
  • 7.5.1. By Devices
  • 7.5.2. By Application
  • 7.5.3. By Country
    • 7.5.3.1. Israel
      • 7.5.3.1.1. Market Opportunities and Trends
      • 7.5.3.1.2. Growth Prospects
    • 7.5.3.2. Saudi Arabia
      • 7.5.3.2.1. Market Opportunities and Trends
      • 7.5.3.2.2. Growth Prospects
    • 7.5.3.3. Others
      • 7.5.3.3.1. Market Opportunities and Trends
      • 7.5.3.3.2. Growth Prospects
• 7.6. Asia Pacific
  • 7.6.1. By Devices
  • 7.6.2. By Application
  • 7.6.3. By Country
    • 7.6.3.1. China
      • 7.6.3.1.1. Market Opportunities and Trends
      • 7.6.3.1.2. Growth Prospects
    • 7.6.3.2. Japan
      • 7.6.3.2.1. Market Opportunities and Trends
      • 7.6.3.2.2. Growth Prospects
    • 7.6.3.3. India
      • 7.6.3.3.1. Market Opportunities and Trends
      • 7.6.3.3.2. Growth Prospects
    • 7.6.3.4. Australia
      • 7.6.3.4.1. Market Opportunities and Trends
      • 7.6.3.4.2. Growth Prospects
    • 7.6.3.5. South Korea
      • 7.6.3.5.1. Market Opportunities and Trends
      • 7.6.3.5.2. Growth Prospects
    • 7.6.3.6. Taiwan
      • 7.6.3.6.1. Market Opportunities and Trends
      • 7.6.3.6.2. Growth Prospects
    • 7.6.3.7. Thailand
      • 7.6.3.7.1. Market Opportunities and Trends
      • 7.6.3.7.2. Growth Prospects
    • 7.6.3.8. Indonesia
      • 7.6.3.8.1. Market Opportunities and Trends
      • 7.6.3.8.2. Growth Prospects
    • 7.6.3.9. Others
      • 7.6.3.9.1. Market Opportunities and Trends
      • 7.6.3.9.2. Growth Prospects

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 8.1. Major Players and Strategy Analysis
• 8.2. Market Share Analysis
• 8.3. Mergers, Acquisitions, Agreements, and Collaborations
• 8.4. Competitive Dashboard

9. COMPANY PROFILES

• 9.1. NeuroMetrix, Inc.
• 9.2. Medtronic
• 9.3. Boston Scientific Corporation
• 9.4. Zynex Medical
• 9.5. BioElectronics Corporation
• 9.6. Pain Management Technologies
• 9.7. SPR Therapeutics
• 9.8. Becton, Dickinson, and Company
• 9.9. Abbott
• 9.10. Nevro Corp